Physiologically based pharmacokinetic/toxicokinetic modeling.

Physiologically based pharmacokinetic (PBPK) models differ from conventional compartmental pharmacokinetic models in that they are based to a large extent on the actual physiology of the organism. The application of pharmacokinetics to toxicology or risk assessment requires that the toxic effects in a particular tissue are related in some way to the concentration time course of an active form of the substance in that tissue. The motivation for applying pharmacokinetics is the expectation that the observed effects of a chemical will be more simply and directly related to a measure of target tissue exposure than to a measure of administered dose. The goal of this work is to provide the reader with an understanding of PBPK modeling and its utility as well as the procedures used in the development and implementation of a model to chemical safety assessment using the styrene PBPK model as an example.

[1]  M E Andersen,et al.  Saturable metabolism and its relationship to toxicity. , 1981, Critical reviews in toxicology.

[2]  Melvin E. Andersen,et al.  Gas Uptake Inhalation Techniques and the Rates of Metabolism of Chloromethanes, Chloroethanes, and Chloroethylenes in the Rat , 1990 .

[3]  B C Allen,et al.  Pharmacokinetic modeling of trichloroethylene and trichloroacetic acid in humans. , 1993, Risk analysis : an official publication of the Society for Risk Analysis.

[4]  A. Monro,et al.  What is an appropriate measure of exposure when testing drugs for carcinogenicity in rodents? , 1992, Toxicology and applied pharmacology.

[5]  Malcolm Rowland,et al.  Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). , 2004, AAPS pharmSci.

[6]  Hiroshi Yamazaki,et al.  Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling. , 2010, Regulatory toxicology and pharmacology : RTP.

[7]  Melvin E. Andersen,et al.  Competitive Inhibition of Thyroidal Uptake of Dietary Iodide by Perchlorate Does Not Describe Perturbations in Rat Serum Total T4 and TSH , 2009, Environmental health perspectives.

[8]  H J Clewell,et al.  Risk assessment of chemical mixtures: biologic and toxicologic issues. , 1993, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[9]  G. W. Jepson,et al.  Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters. , 1994, Environmental health perspectives.

[10]  M. Andersen,et al.  Inhalation pharmacokinetics: evaluating systemic extraction, total in vivo metabolism, and the time course of enzyme induction for inhaled styrene in rats based on arterial blood:inhaled air concentration ratios. , 1984, Toxicology and applied pharmacology.

[11]  P O Droz,et al.  A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans. , 1996, Toxicology and applied pharmacology.

[12]  Melvin E. Andersen,et al.  Use of a Physiologically Based Pharmacokinetic Model and Computer Simulation for Retrospective Assessment of Exposure to Volatile Toxicants , 1990 .

[13]  H J Clewell,et al.  Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. , 1996, Toxicology.

[14]  Melvin E. Andersen,et al.  Physiologically based pharmacokinetic and pharmacodynamic model for the inhibition of acetylcholinesterase by diisopropyfluorophosphate , 1990 .

[15]  K. Bischoff,et al.  Methotrexate pharmacokinetics. , 1971, Journal of pharmaceutical sciences.

[16]  P O Droz,et al.  A physiologically based pharmacokinetic model for arsenic exposure. I. Development in hamsters and rabbits. , 1996, Toxicology and applied pharmacology.

[17]  M E Andersen,et al.  Determining kinetic constants of chlorinated ethane metabolism in the rat from rates of exhalation. , 1989, Toxicology and applied pharmacology.

[18]  Rebecca A Clewell,et al.  Predicting fetal perchlorate dose and inhibition of iodide kinetics during gestation: a physiologically-based pharmacokinetic analysis of perchlorate and iodide kinetics in the rat. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[19]  M E Andersen,et al.  Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. , 1989, Toxicology and applied pharmacology.

[20]  G. W. Jepson,et al.  Cardiac sensitization thresholds of halon replacement chemicals predicted in humans by physiologically-based pharmacokinetic modeling. , 1996, Risk analysis : an official publication of the Society for Risk Analysis.

[21]  M. Andersen,et al.  Gas uptake studies of deuterium isotope effects on dichloromethane metabolism in female B6C3F1 mice in vivo. , 1994, Toxicology and applied pharmacology.

[22]  E J O'Flaherty,et al.  Physiologically based models for bone-seeking elements. IV. Kinetics of lead disposition in humans. , 1993, Toxicology and applied pharmacology.

[23]  P. Åstrand,et al.  Textbook of Work Physiology , 1970 .

[24]  H J Clewell,et al.  A physiological pharmacokinetic model for dermal absorption of vapors in the rat. , 1986, Toxicology and applied pharmacology.

[25]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[26]  M. Andersen,et al.  Risk Assessment Extrapolations and Physiological Modeling , 1985, Toxicology and industrial health.

[27]  H J Clewell,et al.  Physiologically-Based Pharmacokinetic Modeling and Bioactivation of Xenobiotics , 1994, Toxicology and industrial health.

[28]  H J Clewell.  Incorporating biological information in quantitative risk assessment: an example with methylene chloride. , 1995, Toxicology.

[29]  H J Clewell,et al.  The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances. , 1995, Toxicology letters.

[30]  R. Lutz,et al.  Comparison of the pharmacokinetics of several polychlorinated biphenyls in mouse, rat, dog, and monkey by means of a physiological pharmacokinetic model. , 1984, Drug metabolism and disposition: the biological fate of chemicals.

[31]  Rebecca A Clewell,et al.  PBPK predictions of perchlorate distribution and its effect on thyroid uptake of radioiodide in the male rat. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[32]  H J Clewell,et al.  Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans. , 1991, Toxicology and applied pharmacology.

[33]  M E Andersen,et al.  Determination of the kinetic constants for metabolism of inhaled toxicants in vivo using gas uptake measurements. , 1980, Toxicology and applied pharmacology.

[34]  Ellen J. O'Flaherty,et al.  Physiologically based models for bone-seeking elements , 1991 .

[35]  E. O'flaherty,et al.  Physiologically based models for bone-seeking elements. III. Human skeletal and bone growth. , 1991, Toxicology and applied pharmacology.

[36]  E. Adolph,et al.  Quantitative Relations in the Physiological Constitutions of Mammals. , 1949, Science.

[37]  M E Andersen,et al.  Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment. , 1993, Risk analysis : an official publication of the Society for Risk Analysis.

[38]  R L Dedrick,et al.  Species similarities in pharmacokinetics. , 1980, Federation proceedings.

[39]  Vera Thomas.  Biological-Mathematical Modeling of Chronic Toxicity. , 1981 .

[40]  Melvin E Andersen,et al.  Characterization of the Pharmacokinetics of Gasoline Using PBPK Modeling with a Complex Mixtures Chemical Lumping Approach , 2003, Inhalation toxicology.

[41]  A Sato,et al.  Partition coefficients of some aromatic hydrocarbons and ketones in water, blood and oil. , 1979, British journal of industrial medicine.

[42]  Jeffrey W Fisher,et al.  A PBPK Modeling Assessment of the Competitive Metabolic Interactions of JP-8 Vapor with Two Constituents, m-Xylene and Ethylbenzene , 2007, Inhalation toxicology.

[43]  H J Clewell,et al.  Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment. , 1997, Journal of toxicology and environmental health.

[44]  Malcolm Rowland,et al.  Physiologically based pharmacokinetics in Drug Development and Regulatory Science: A workshop report (Georgetown University, Washington, DC, May 29–30, 2002) , 2004, AAPS PharmSci.

[45]  H J Clewell,et al.  Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.

[46]  H J Clewell,et al.  Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. , 1989, Toxicology and applied pharmacology.

[47]  M L Gargas,et al.  Improving Cancer Dose–Response Characterization by Using Physiologically Based Pharmacokinetic Modeling: An Analysis of Pooled Data for Acrylonitrile‐Induced Brain Tumors to Assess Cancer Potency in the Rat , 2000, Risk analysis : an official publication of the Society for Risk Analysis.

[48]  Robert L. Dedrick,et al.  Animal scale-up , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[49]  R Tardif,et al.  Validation of a physiological modeling framework for simulating the toxicokinetics of chemicals in mixtures. , 2000, Toxicology and applied pharmacology.

[50]  R Tardif,et al.  A PBPK modeling-based approach to account for interactions in the health risk assessment of chemical mixtures. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[51]  Walter Schmitt,et al.  Whole body physiologically-based pharmacokinetic models: their use in clinical drug development , 2008 .

[52]  Aldo Rescigno,et al.  The use and abuse of models , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[53]  H J Clewell,et al.  A physiologically based pharmacokinetic model for retinoic acid and its metabolites. , 1997, Journal of the American Academy of Dermatology.

[54]  J. Young,et al.  Pharmacokinetics of inhaled styrene in human volunteers. , 1980, Toxicology and applied pharmacology.

[55]  G. Johanson,et al.  Physiologically based pharmacokinetic modeling of inhaled 2-butoxyethanol in man. , 1986, Toxicology letters.

[56]  P. Allen,et al.  Physiological model for the pharmacokinetics of methyl mercury in the growing rat. , 1993, Toxicology and applied pharmacology.

[57]  J. O’FlahertyE.  向骨性元素(bone-seeking elements)の生理学に基いたモデル II ラットでの鉛分布速度論 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター , 1991 .

[58]  R. Dedrick,et al.  Cisplatin pharmacokinetics: applications of a physiological model. , 1988, Toxicology letters.

[59]  J. Fisher,et al.  A physiologically based pharmacokinetic model for atrazine and its main metabolites in the adult male C57BL/6 mouse. , 2011, Toxicology and applied pharmacology.

[60]  H J Clewell.  Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing. , 1993, Toxicology letters.

[61]  Torsten Teorell,et al.  Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .

[62]  R K Jain,et al.  Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.

[63]  E J O'Flaherty,et al.  Physiologically based models for bone-seeking elements. V. Lead absorption and disposition in childhood. , 1995, Toxicology and applied pharmacology.

[64]  Rebecca A Clewell,et al.  Predicting neonatal perchlorate dose and inhibition of iodide uptake in the rat during lactation using physiologically-based pharmacokinetic modeling. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[65]  H. B. Matthews,et al.  Enteric transport of chlordecone (Kepone®) in the rat , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[66]  H J Clewell,et al.  Incorporation of pharmacokinetics in noncancer risk assessment: example with chloropentafluorobenzene. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.

[67]  H. J. Clewell,et al.  Pharmacokinetic dose estimates of mercury in children and dose-response curves of performance tests in a large epidemiological study , 1995 .

[68]  M. Andersen,et al.  Oral absorption and oxidative metabolism of atrazine in rats evaluated by physiological modeling approaches. , 2007, Toxicology.

[69]  B C Allen,et al.  Evaluating the risk of liver cancer in humans exposed to trichloroethylene using physiological models. , 1993, Risk analysis : an official publication of the Society for Risk Analysis.

[70]  H A Barton,et al.  Chloroethylene mixtures: pharmacokinetic modeling and in vitro metabolism of vinyl chloride, trichloroethylene, and trans-1,2-dichloroethylene in rat. , 1995, Toxicology and applied pharmacology.

[71]  P. Watanabe,et al.  Fate of (14C)vinyl chloride after single oral administration in rats. , 1976, Toxicology and applied pharmacology.

[72]  H J Clewell,et al.  Metabolism of inhaled dihalomethanes in vivo: differentiation of kinetic constants for two independent pathways. , 1986, Toxicology and applied pharmacology.

[73]  M. Andersen,et al.  Metabolism of inhaled brominated hydrocarbons: validation of gas uptake results by determination of a stable metabolite. , 1982, Toxicology and applied pharmacology.

[74]  M E Andersen,et al.  Estimating the risk of liver cancer associated with human exposures to chloroform using physiologically based pharmacokinetic modeling. , 1990, Toxicology and applied pharmacology.

[75]  H J Clewell,et al.  Quantitative evaluation of the metabolic interactions between trichloroethylene and 1,1-dichloroethylene in vivo using gas uptake methods. , 1987, Toxicology and applied pharmacology.

[76]  Raymond S. H. Yang,et al.  Development of a physiologically based pharmacokinetic model for volatile fractions of gasoline using chemical lumping analysis. , 2004, Environmental science & technology.

[77]  Ewart R. Carson,et al.  The mathematical modeling of metabolic and endocrine systems : model formulation, identification, and validation , 1983 .

[78]  Lisa M Sweeney,et al.  Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humans. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[79]  H. Matthews,et al.  Distribution and excretion of 2,2',4,4',5,5'-hexabromobiphenyl in rats and man: pharmacokinetic model predictions. , 1980, Toxicology and applied pharmacology.

[80]  H J Clewell,et al.  Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. , 1996, Toxicology.

[81]  M E Andersen,et al.  Physiologically based pharmacokinetic modeling with trichloroethylene and its metabolite, trichloroacetic acid, in the rat and mouse. , 1991, Toxicology and applied pharmacology.

[82]  H J Clewell,et al.  Applying simulation modeling to problems in toxicology and risk assessment--a short perspective. , 1995, Toxicology and applied pharmacology.

[83]  Timothy R. Gerrity,et al.  Principles of route-to-route extrapolation for risk assessment : proceedings of the Workshops on Principles of Route-to-Route Extrapolation for Risk Assessment held March 19-21, 1990, in Hilton Head, South Carolina and July 10-11, 1990, in Durham, North Carolina , 1990 .

[84]  D J Paustenbach,et al.  A physiologically based pharmacokinetic model for inhaled carbon tetrachloride. , 1988, Toxicology and applied pharmacology.

[85]  H J Clewell,et al.  Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethylene. , 1995, Chemosphere.

[86]  H. Bolt,et al.  Pharmacokinetics of halogenated ethylenes in rats , 1978, Archives of Toxicology.

[87]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[88]  John F. Young,et al.  A physiologically based pharmacokinetic computer model for human pregnancy. , 1994, Teratology.

[89]  M E Andersen,et al.  A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. , 1984, Toxicology and applied pharmacology.

[90]  R. D. Stewart,et al.  Human exposure to styrene vapor. , 1968, Archives of environmental health.

[91]  R H Reitz,et al.  In vitro metabolism of methylene chloride in human and animal tissues: use in physiologically based pharmacokinetic models. , 1989, Toxicology and applied pharmacology.

[92]  Jeffery M. Gearhart,et al.  A Partition Coefficient Determination Method for Nonvolatile Chemicals in Biological Tissues , 1994 .

[93]  L S Birnbaum,et al.  Physiological model for the pharmacokinetics of 2,3,7,8-tetrachlorodibenzofuran in several species. , 1983, Toxicology and applied pharmacology.

[94]  H W Leung,et al.  Development and utilization of physiologically based pharmacokinetic models for toxicological applications. , 1991, Journal of toxicology and environmental health.

[95]  M E Andersen,et al.  Physiological model for tissue glutathione depletion and increased resynthesis after ethylene dichloride exposure. , 1988, The Journal of pharmacology and experimental therapeutics.

[96]  H J Clewell,et al.  A physiologically based simulation approach for determining metabolic constants from gas uptake data. , 1986, Toxicology and applied pharmacology.

[97]  M E Andersen,et al.  Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. , 1995, Risk analysis : an official publication of the Society for Risk Analysis.

[98]  J. Young,et al.  Pharmacokinetics of inhaled styrene in rats and humans. , 1978, Scandinavian journal of work, environment & health.

[99]  F E Yates.  Good manners in good modeling: mathematical models and computer simulations of physiological systems. , 1978, The American journal of physiology.

[100]  H J Clewell,et al.  Improving toxicology testing protocols using computer simulations. , 1989, Toxicology letters.

[101]  R. Clewell,et al.  The use of physiologically based models to integrate diverse data sets and reduce uncertainty in the prediction of perchlorate and iodide kinetics across life stages and species , 2001, Toxicology and industrial health.

[102]  Rebecca A Clewell,et al.  PBPK model for radioactive iodide and perchlorate kinetics and perchlorate-induced inhibition of iodide uptake in humans. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[103]  W. S. Snyder,et al.  Report of the task group on reference man , 1979, Annals of the ICRP.

[104]  D J Paustenbach,et al.  A physiologically based pharmacokinetic model for 2,3,7,8-tetrachlorodibenzo-p-dioxin in C57BL/6J and DBA/2J mice. , 1988, Toxicology letters.

[105]  A Sato,et al.  A vial-equilibration method to evaluate the drug-metabolizing enzyme activity for volatile hydrocarbons. , 1979, Toxicology and applied pharmacology.

[106]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[107]  W. L. Chiou,et al.  Determination of tissue to blood partition coefficients in physiologically-based pharmacokinetic studies. , 1982, Journal of pharmaceutical sciences.

[108]  E. O'flaherty.  PBK modeling for metals. Examples with lead, uranium, and chromium. , 1995, Toxicology letters.

[109]  R. J. Lutz,et al.  A review of the applications of physiologically based pharmacokinetic modeling , 1979, Journal of Pharmacokinetics and Biopharmaceutics.

[110]  M E Andersen,et al.  Development of a physiologically based pharmacokinetic model for chloroform. , 1990, Toxicology and applied pharmacology.

[111]  D. H. Taylor,et al.  Physiologically based pharmacokinetic modeling of the lactating rat and nursing pup: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. , 1990, Toxicology and applied pharmacology.